Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma

Highly sensitive reporter-gene assays have been developed that allow both the direct vascular endothelial growth factor (VEGF) neutralizing activity of bevacizumab and the ability of bevacizumab to activate antibody dependent cellular cytotoxicity (ADCC) to be quantified rapidly and in a highly spec...

Full description

Bibliographic Details
Main Authors: Christophe Lallemand, Rosa Ferrando-Miguel, Michael Auer, Sarah Iglseder, Theresa Czech, Anouk Gaber-Wagener, Franziska Di Pauli, Florian Deisenhammer, Michael G. Tovey
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
bevacizumab
ADCC
glioblastoma
ovarian cancer
VEGF
bioassay
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.515556/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.515556/full

Similar Items